The company informed the Bombay Stock Exchange that it got the approval for marketing the antibiotic in strengths of 50mg, 75mg and 100mg.
Doxycycline is indicated for a variety of infections caused by susceptible strains or micro-organisms including respiratory tract and urinary tract infections, skin and skin structure infections, it added.
The USFDA's office of Generic Drugs, has determined the company's formulations to be bioequivalent and having the same therapeutic effect as that of the branded drug Adoxa, marketed by Bioglan Pharmaceutical Co, Ranbaxy added.